Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Antibody symbols : SRNE save search
Antibody Drug Conjugate - Competitive Landscape 2023 Study: Featuring Coverage on 180+ Companies and 300+ Drugs
Published: 2023-06-30 (Crawled : 18:00) - prnewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
IMGN | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
drug companies antibody
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Published: 2023-06-05 (Crawled : 13:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.66%
H: 6.33%
C: 5.6%
esg401 drug antibody asco tumors positive meeting results study
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)
Published: 2022-10-14 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
| Email alert
Add to watchlist
sti-9167 preclinical antibody sars-cov-2 publication
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.0%
H: 8.61%
C: 7.28%
sti-9199 antibody enroll
Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
Published: 2022-04-25 (Crawled : 14:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.0%
H: 5.26%
C: 2.92%
sti-9167 fda antibody sars-cov-2 authorization phase 1
Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants
Published: 2022-03-20 (Crawled : 00:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.44%
H: 1.48%
C: -7.38%
covid-19 covid report results vaccine antibody
Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
sti-9199 covid-19 fda covid phase 1 authorization antibody
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
Published: 2022-03-02 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
sti-9199 sars-cov-2 drop antibody infection infections
Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses
Published: 2022-02-22 (Crawled : 18:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.75%
H: 3.39%
C: -0.71%
sti-9167 antibody
SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS OF SARS-COV-2
Published: 2022-01-20 (Crawled : 19:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.47%
H: 5.59%
C: -2.8%
sti-9167 therapeutics sars-cov-2 antibody
WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
Published: 2021-12-28 (Crawled : 01:00) - prnewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.26%
H: 1.45%
C: -10.73%
cd47 antibody
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.15%
H: 5.26%
C: 2.92%
treatment cancer antibody license
Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors
Published: 2021-10-13 (Crawled : 14:15) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda clearance fda solid tumors antibody drug trial clearance
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Published: 2021-07-23 (Crawled : 16:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -5.13%
treatment lung cancer cancer antibody license
Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors
Published: 2021-07-21 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.22%
H: 1.91%
C: -1.35%
solid tumors clinical trials antibody drug trial clearance
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern
Published: 2021-07-21 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.08%
H: 8.91%
C: 7.24%
covid phase 2 drop antibody trial sars-cov-2
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
Published: 2021-07-21 (Crawled : 14:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.08%
H: 8.91%
C: 7.24%
covid phase 2 drop antibody trial sars-cov-2
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
Published: 2021-04-27 (Crawled : 16:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.43%
H: 9.54%
C: 6.4%
fda clearance fda phase 2 antibody clearance urothelial carcinoma
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
Published: 2021-03-18 (Crawled : 13:30) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.2%
H: 2.83%
C: -4.35%
antibody drug trial als
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.